Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Methylnaltrexone Bromide

FDA-approved product (solution, subcutaneous), marketed as Methylnaltrexone Bromide, Relistor.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Methylnaltrexone Bromide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Constipation
  • Opioid dependence

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Peripheral opioid receptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Methylnaltrexone Bromide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Methylnaltrexone Bromide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Effect of Methylnaltrexone (Relistor) on Digestion and Tolerance to Tube Feeding in Patients Treated With Opiates

    NCT01360372 · start 2010-10

    Registered record
    Registry ID
    NCT01360372
    Conditions
    Tube Feeding
    Interventions
    Methylnaltrexone; Saline injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2010-10
    Completion
    2012-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTube Feeding
    InterventionMethylnaltrexone; Saline injection
    PhasePhase 3
    Registry statusWithdrawn

  • A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation (OIC) in Participants With Chronic, Non-Malignant Pain

    NCT01186770 · start 2010-09-01

    Registered record
    Registry ID
    NCT01186770
    Conditions
    Opioid-Induced Constipation
    Interventions
    Methylnaltrexone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09-01
    Completion
    2011-09-08
    Enrolment
    804

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Induced Constipation
    InterventionMethylnaltrexone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects

    NCT01366326 · start 2010-07

    Registered record
    Registry ID
    NCT01366326
    Conditions
    Healthy Adult Subjects
    Interventions
    Methylnaltrexone bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-07
    Completion
    2010-08
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Subjects
    InterventionMethylnaltrexone bromide
    PhasePhase 1
    Registry statusCompleted

  • Effects of 500 mg Immediate Release and Extended Release Methylnaltrexone on Loperamide-induced Delay of the Oro-cecal and Whole-gut Transit Time in Healthy Subjects

    NCT01596777 · start 2010-01

    Registered record
    Registry ID
    NCT01596777
    Conditions
    Intestinal Obstruction
    Interventions
    Loperamide; Loperamide placebo; Methylnaltrexone placebo; Methylnaltrexone 12 mg sc.; Methylnaltrexone IR capsule; Methylnaltrexone ER capsule; Colon Transit; Sulfasalazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-05
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntestinal Obstruction
    InterventionLoperamide; Loperamide placebo; Methylnaltrexone placebo; Methylnaltrexone 12 mg sc. +4 more
    PhasePhase 1
    Registry statusCompleted

  • Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

    NCT01050595 · start 2009-12

    Registered record
    Registry ID
    NCT01050595
    Conditions
    Opioid-induced Constipation
    Interventions
    Methylnaltrexone Bromide; Placebo-Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2009-12
    Completion
    2010-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-induced Constipation
    InterventionMethylnaltrexone Bromide; Placebo-Normal Saline
    PhasePhase 3
    Registry statusUnknown

  • Opioids and Esophageal Function

    NCT01012960 · start 2009-11

    Registered record
    Registry ID
    NCT01012960
    Conditions
    Pharyngeal Dysfunction; Esophageal Dysfunction
    Interventions
    methylnaltrexone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-01
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharyngeal Dysfunction; Esophageal Dysfunction
    Interventionmethylnaltrexone
    PhasePhase 4
    Registry statusCompleted

  • Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

    NCT01015222 · start 2009-11

    Registered record
    Registry ID
    NCT01015222
    Conditions
    Advanced Cancer
    Interventions
    Dasatinib; Bevacizumab; Paclitaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2009-11
    Completion
    2021-05-27
    Enrolment
    122

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Cancer
    InterventionDasatinib; Bevacizumab; Paclitaxel
    PhasePhase 1
    Registry statusCompleted

  • Effect of Methylnaltrexone on GI Transit in Healthy Volunteers

    NCT01055704 · start 2009-11

    Registered record
    Registry ID
    NCT01055704
    Conditions
    Gastric Motility Disorder
    Interventions
    Methylnaltrexone only; Codeine only; Methylnaltrexone + codeine; Placebo + placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-02
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastric Motility Disorder
    InterventionMethylnaltrexone only; Codeine only; Methylnaltrexone + codeine; Placebo + placebo
    PhasePhase 4
    Registry statusCompleted

  • Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

    NCT01004393 · start 2009-10

    Registered record
    Registry ID
    NCT01004393
    Conditions
    Neoplasms; Constipation; Opioid-Related Disorders
    Interventions
    Methylnaltrexone bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2013-12
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms; Constipation; Opioid-Related Disorders
    InterventionMethylnaltrexone bromide
    PhasePhase 2
    Registry statusCompleted

  • Can Methylnaltrexone Safely Treat Opioid Related Constipation in the Emergency Department?

    NCT00949377 · start 2009-09

    Registered record
    Registry ID
    NCT00949377
    Conditions
    Colonic Inertia
    Interventions
    Methylnaltrexone Bromide (MNTX); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-09
    Completion
    2011-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionColonic Inertia
    InterventionMethylnaltrexone Bromide (MNTX); Placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Study Evaluating the Efficacy and Safety of Subcutaneous Methylnaltrexone (MOA-728) for the Treatment of Opioid-Induced-Constipation

    NCT00936884 · start 2009-07

    Registered record
    Registry ID
    NCT00936884
    Conditions
    Constipation
    Interventions
    Methylnaltrexone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-07
    Completion
    2013-11
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionMethylnaltrexone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study Evaluating Safety & Efficacy of Subcutaneous Methylnaltrexone on Opioid-Induced Constipation in Cancer Subjects

    NCT00858754 · start 2009-03

    Registered record
    Registry ID
    NCT00858754
    Conditions
    Opioid-Induced Constipation
    Interventions
    methylnaltrexone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2009-03
    Completion
    2009-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Induced Constipation
    Interventionmethylnaltrexone; placebo
    PhasePhase 4
    Registry statusWithdrawn

  • Study Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation

    NCT00804141 · start 2008-12-03

    Registered record
    Registry ID
    NCT00804141
    Conditions
    Constipation
    Interventions
    N-methylnaltrexone bromide (MOA-728)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-12-03
    Completion
    2010-09-20
    Enrolment
    1,040

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionN-methylnaltrexone bromide (MOA-728)
    PhasePhase 3
    Registry statusCompleted

  • Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness

    NCT00672139 · start 2008-07

    Registered record
    Registry ID
    NCT00672139
    Conditions
    Opioid-Induced Constipation
    Interventions
    Methylnaltrexone bromide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-07
    Completion
    2013-05
    Enrolment
    156

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Induced Constipation
    InterventionMethylnaltrexone bromide
    PhasePhase 4
    Registry statusCompleted

  • Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

    NCT00640146 · start 2007-10-19

    Registered record
    Registry ID
    NCT00640146
    Conditions
    Opioid-induced Constipation
    Interventions
    Methylnaltrexone bromide; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-10-19
    Completion
    2009-01-21
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-induced Constipation
    InterventionMethylnaltrexone bromide; Placebo
    PhasePhase 2
    Registry statusCompleted